10,905
Total Publications
558,690
Total Citations
Top Researchers
- George Kuo 29,028 citations • 168 papers
- Jen‐Shi Chen 24,233 citations • 305 papers
- Wen‐Hung Chung 20,483 citations • 385 papers
- Yee‐Chun Chen 19,641 citations • 756 papers
- Rong‐Nan Chien 19,583 citations • 346 papers
- Grant D. Huang 18,804 citations • 192 papers
- T.‐C. Wu 18,050 citations • 417 papers
- Cheng‐Hsun Chiu 17,668 citations • 589 papers
- Wen‐Jone Chen 17,127 citations • 835 papers
- Chee‐Jen Chang 16,674 citations • 348 papers
Most Cited Papers
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial 2017 • 2,256 citations
- Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos) 2017 • 1,413 citations
- Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study 2012 • 1,214 citations
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer 2022 • 1,025 citations
- Shedding the cobra effect: problematising thematic emergence, triangulation, saturation and member checking 2016 • 964 citations
- Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update 2019 • 865 citations
- Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis 2017 • 841 citations
- Molecular International Prognostic Scoring System for Myelodysplastic Syndromes 2022 • 780 citations
- Gut commensal <i>Parabacteroides goldsteinii</i> plays a predominant role in the anti-obesity effects of polysaccharides isolated from <i>Hirsutella sinensis</i> 2018 • 764 citations
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial 2022 • 737 citations